CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Treatment for Methamphetamine Addiction: A Review of Guidelines

Last updated: July 2, 2019
Project Number: RC1146-000
Product Line: Rapid Response
Research Type: Devices and Systems
Report Type: Summary with Critical Appraisal
Result type: Report


  1. What are the evidence-based guidelines regarding the treatment for patients with methamphetamine addiction immediately after acute detoxification?
  2. What are the evidence-based guidelines regarding post-treatment care for patients with methamphetamine addiction?

Key Message

Three evidence-based guidelines were identified that addressed the research questions. Although published separately, all three publications represented one unique guideline; therefore, one evidence-based guideline is reported. A variety of recommendations were made regarding treatment immediately after acute detoxification and post-treatment care for patients with methamphetamine addiction. Needs-centred or motivation-centred psychotherapeutic counseling, sports therapy such as exercise therapy and physical conditioning were recommended by the guideline. The guideline recommended that sertraline, combined intravenous pharmacotherapy with flumazenil, gabapentin and hydroxyzine should not be given to patients with methamphetamine-related disorder. The guideline also recommended that needs-specific self-help groups and family support should be an integral part of all services offered.